Katy K. Tsai

MD

Oncologist and melanoma specialist

About me

Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers.

In addition to caring for patients, Tsai conducts clinical trials with two of her colleagues in cutaneous oncology, Dr. Adil Daud and Dr. Alain Algazi, seeking new and better therapies for patients with advanced melanoma or head and neck cancers. She also has a long-standing research interest in quality of life and outcomes for patients receiving immunotherapy.

Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow.

Tsai is a member of the American Society of Clinical Oncology. She was born in Taiwan and raised in Toronto.

  • Education

    Brown University School of Medicine, 2010

  • Residencies

    University of North Carolina School of Medicine, Internal Medicine, 2013

  • Fellowships

    UCSF, Medical Oncology, 2015

  • Academic Title

    Assistant Professor

Melanoma & Skin Cancer Program

Bakar Precision Cancer Medicine Building

1825 Fourth Street, Third Floor
San Francisco, CA 94158

(415) 353-7817

My reviews

4.9

Overall Experience
160 Reviews
we were VERY impressed with Dr. Tsai and her listening to and responding to our questions as well as establishing a plan to get answers to determine the extent of my cancer
Explained things in a way that was easy to understand
159 Reviews
Did the doctor pay attention to your concerns
158 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
156 Reviews
Knew the important information about your medical history
158 Reviews
The provider showed respect for what you had to say
159 Reviews
The provider spent enough time with me
159 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

RFS is defined as time from registration to recurrence of disease or death from any cause.

Recruiting

Decorative Caduceus

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Percentage of subjects with adverse events (AEs)

Recruiting

Contact me

Providers on my team

Share